Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-08-21
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotechnology company using an AI-native drug discovery system, automated labs, and proprietary data to build internal medicines and partner programs.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof Gates Define a Real Upside
The opportunity is no longer just abstract AI promise. The investment case now depends on whether one lead asset and one follow-on program can turn a strong discovery engine into repeatable clinical proof and better revenue quality by 2031.

Analysis

Thesis
Recursion can graduate from an AI-biotech story to an early drug engine if REC-4881 secures an approval-oriented path and at least one more internal asset reaches credible human proof, allowing its proprietary data-and-lab loop to monetize through product, milestone, and royalty revenue rather than mostly lumpy collaboration revenue.
Last Economy Alignment
Positive because Recursion owns scarce AI-era control points in drug discovery: proprietary wet-lab data, integrated workflows, and dedicated compute. Pricing is not seat-based, so value capture is less exposed to software deflation; the main limiter is that clinical and regulatory proof still decides whether the engine earns durable economics.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.2x (from 5 most recent analyses)
Reasoning
The upside is a proof-and-mix-change story. If the lead rare-disease asset becomes commercially credible, one oncology asset adds real human validation, and external work becomes more standardized, investors can value the business less like a speculative platform and more like an early commercial medicine engine with recurring downstream economics.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is not whether Recursion can generate more AI output; it is whether that output becomes repeatable human and regulatory proof before financing leverage weakens. REC-4881 path clarity is the first gate, a second internal proof asset is the next gate, and both matter more than incremental model quality improvements.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.58
They own a data-and-lab engine that can make drug discovery faster and smarter, and every successful program feeds more learning back into the system. The risk is that regulators and human trial results, not AI speed alone, decide whether that engine becomes real medicines and lasting profits.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.22
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case